Layer, Chiang, et al. Genome Biology
Quark Begins Patient Dosing in Phase I Study of Ocular Neuroprotectant
Although Quark initially expects to market the drug as a treatment for a rare condition known as non-arteritic anterior ischemic optic neuropathy, it hopes it can eventually develop it as a glaucoma treatment.
New to GenomeWeb? Register here quickly.